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Abstract
Background: The role of estrogen receptor alpha (ERa), estrogen receptor beta (ERb) and ERa36 signaling in
hepatocellular carcinoma (HCC) is not fully addressed.
Methods: In this study, three cohorts were included: (i) primary HCC patients (N = 76, cohort P), (ii) colorectal liver
metastasis (mCRC) (N = 32, cohort S), and (iii) HCC from The Cancer Genome Atlas (TCGA) (N = 121). The levels of
ERa36 and wtER36 were measured and their correlation with clinicopathologic features was determined.
Results: WtERa was downregulated and that ERa36 was upregulated in tumor tissues in both cohort P and
TCGA data set. ERa36 was downregulated in tumor tissues in cohort S. In cohort P, wtERa was differentially
expressed in gender (P < 0.000), age (P = 0.004), tumor number (P = 0.043), tumor size (P = 0.002), intrahepatic
recurrence (P = 0.054). ERa36 was unequally expressed in different non-tumor liver status (P = 0.040). WtERa
was negatively associated with overall survival (OS) and disease free survival (DFS) in cohort P. Compared
with non-tumor tissues, the expression of ERa36 was increased in primary HCC but decreased in secondary
HCC, showing opposite expression patterns of ERa36 between primary HCC and secondary HCC.
Conclusions: Primary HCC is associated with the decreased WtERa but increased ERa36. The expression
pattern of ERa36 is different between primary HCC and secondary HCC, as the former with the increased
ERa36 but the latter with the decreased ERa36. Therefore, the expression of ERa36 may be used to
differentiate the primary HCC and the secondary one.
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Background
Despite decades of research, the etiology of HCC remains
unclear. Hepatocellular carcinoma (HCC) is a common
cancer and leading cause of cancer death worldwide [1].
While rates of new cases and deaths have fallen steadily in
recent years, these declines have been slow in magnitude
compared with other cancers. Therefore, the prevention
and treatment of HCC remain unmet needs. The identifi-
cation of key biomarkers with prognostic value would help
guide future clinical trials of HCC therapies.
Estrogens play an important role in normal liver func-
tion as well as HCC progression [2]. The classical two
receptors of estrogen are estrogen receptor alpha (ERa)
and beta (ERb), and ERa is the dominant ER receptor in
hepatocytes [3]. ERα and its’ variants are expressed in
HCC, and the presence of ERa has been regarded as an
indicator for anti-hormonal (tamoxifen) therapy [4, 5].
However, tamoxifen did not improve the survival or
quality of life in advanced stage HCC patients [6, 7] and
further clinical development was stopped. The presence
of ER transcripts in inoperable HCC is a strong negative
predictor of survival [8].
Alternative splicing has critical roles in normal devel-
opment and can promote growth and survival in cancer
[9]. Due to alternative RNA splicing, several ER isoforms
are formed. So far, at least three ERa isoforms have been
identified, and their molecular weights are 66, 46 and
36 kDa respectively [10]. Compared with ERa66 or
ERa46, ER-a36 is different in its structure, expression
pattern and function [11].
* Correspondence: gchen@cuhk.edu.hk; paullai@surgery.cuhk.edu.hk
1Department of Surgery, The Chinese University of Hong Kong, Prince of
Wales Hospital, Shatin, New Territories, Hong Kong, Special Administrative
Region of China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. BMC Cancer  (2016) 16:926 
DOI 10.1186/s12885-016-2928-3
In this study, we analyzed the expression of wtERa and
ERa36 in HCC biopsy samples using two cohorts of
tissues annotated for relevant histological and clinical
variables. We then assessed the relationship of these
markers with patients’ survival. In addition, alterations
in ER mRNA and protein expression and their relation-
ships with overall survival (OS) and disease-free survival
(DFS) were evaluated using data from TCGA.
Methods
Patients and samples
Tumor samples were collected from 108 HCC patients
who underwent surgery at the Prince of Wales Hospital,
Hong Kong during 2000 to 2014. All patients were
tested positive for HBsAg and negative for antibodies to
the hepatitis C virus (anti-HCV) and human immuno-
deficiency virus (anti-HIV). All tumor tissues were histo-
logically diagnosed and the stages at diagnosis were
classified according to the criteria of the American Joint
Committee on Cancer criteria. Tumor samples were
divided into two cohorts: cohort P (n = 76), primary
HCC patients, and cohort S (n = 32), colorectal liver
metastasis (mCRC). All patients were successfully
followed-up for 1203.5 ± 128.8 days (mean ± SD). All
subjects provided their written informed consent prior
to specimen collection. The study was carried out with
the approval of the Joint CUHK-NTEC Clinical Re-
search Ethics committee. The characteristics of patients
were presented in Table 1. Detailed clinical and patho-
logical information were available for most of these
cases, including patients’ demographic data, pathologic
tumor-node-metastasis (TNM) staging, OS time, and
disease-free survival (DFS) time. Gender was well
balanced in both of the cohorts.
Immunohistochemistry and analysis
The expression of wtERa was determined by immuno-
histochemical assay on paraffin-embedded tissue sec-
tions (5 μm). Sections were deparaffinized in xylene and
dehydrated in series of graded ethanol. Antigen retrieval
was carried out in microwave oven with 10 mM sodium
citrate buffer (pH 6.0). The endogenous peroxidase
activity was inhibited by incubating the tissues with 3 %
H2O2 in TBS for 5 min and nonspecific binding sites
were blocked by incubating with 5 % normal horse
serum for another 30 min. The sections were then incu-
bated in a humidified chamber overnight at 4 °C with
primary rabbit antibody wtERα (Santa Cruz, SC-
130072), ERa36 (Abgent, AP19657b), or ERb (Santa
Cruz, SC-53494). The primary antibody was then rinsed
by tris-buffered saline (TBS) at pH 7.4. Labeling was
carried out with Vector Rabbit ImmPress HRP micropo-
lymer for 30 min at room temperature. Target antigens
were visualized with Vector ImmPACT DAB EqV
Peroxidase (HRP) substrate.
Slides were counterstained with hematoxylin and
prepared for evaluation. The results were examined by
two pathologists independently. Cytoplasmic and/or
membranous expression intensity and density were semi-
Table 1 Patients’ characteristics in primary HCC (cohort P) and
secondary HCC (cohort S) from mCRC





Age (y) ≤58 32 13 0.887
>58 44 19
Gender Female 39 14 0.473
Male 37 18
Liver cirrhosis No 26 31 0.000
Yes 50 1




A 73 32 0.553
NA 3 0
AFP ≤18 ng/ml 33 30 0.000
>18 ng/ml 42 2
Tumor size ≤5 cm 51 26 0.138
>5 cm 25 6
Tumor number Single 61 20 0.052
Multiple 15 12
Vascular invasion No 63 29 0.384
Yes 13 3










Yes 18 18 0.001
No 58 14
Intra-hepatic recurrence No 44 29 0.001
Yes 32 3
Extra-hepatic metastasis No 63 26 0.838
Yes 13 6
AJCC Stage 1 52 NA NA
2 16 NA
3 + 3A 8 NA
Abbreviations: AFP alpha-fetoprotein, AJCC American Joint Committee on
Cancer, NA not available; Neo-adjuvant treatments before operation, including
chemotherapy, preoperative portal vein embolization (PVE) and transcatheter
arterial chemoembolization (TACE); Adjuvant treatments after operation,
including lipiodol-iodine-131, chemotherapy, TACE
Significant data are highlighted in bold
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quantified using a six-value score (0 to 5) as follows: no
staining or staining observed in <30 % of tumor cells was
scored as 0 or 1+; Very weak positive or weak positive
staining in ⩾30 % and <60 % of tumor cells was scored
as 2+ and 3+; and positive or strong positive staining
in ⩾60 % of tumor cells was scored as 4+ and 5+,
respectively. A tumor sample was considered positive
if the score was above the median value of all samples
and negative otherwise.
Analysis of ERa alternative splicing from TCGA
The alternative splicing of ERa was generated from RNA-
seq data which were acquired from TCGA data portal by
TCGA SpliceSeq database [12]. Based on the coverage of
different splicing isoforms, each alternative splicing event
was assigned with a PSI (Percent Spliced In) value ranging
from 0 to 1. To increase the read coverage, we filtered out
low coverage samples with less than 500 reads. Independ-
ent t test was used to compare the difference between
tumor and adjacent non-tumor tissues. Correlations be-
tween ERa mRNA expression and alternative splicing
events were calculated using the spearman rank correl-
ation, ρ (rho). We obtained the overall survival data of
LIHC patients from TCGA and computed their probabil-
ity of survival using a Kaplan-Meier survival plot and the
log-rank P values.
Statistical analysis
The differences of clinical features between two co-
horts were evaluated using Chi-square tests (2-sided).
The summary statistics for the biomarker expression
levels according to patients’ characteristics were com-
puted. The Pearson/nonparametric correlation test
and t test were used to compare biomarker expres-
sion among different subgroups defined by clinical
features, such as gender, pathological stage and tumor
size. The OS and DFS of each subgroup of patients
were determined by the Kaplan–Meier method and
compared using the log-rank test. Cox proportional
hazard models were used for multivariate analyses.
The expression of wtERa, ERa36, ERb, age, gender,
AFP (ng/ml), tumor number, tumor size (cm), vascu-
lar invasion, intra-hepatic recurrence, extra-hepatic
metastasis, neo-adjuvant treatments, adjuvant treat-
ments, liver cirrhosis and HBsAg status were included
in multivariate analyses. All statistical tests were two-
sided, and P ≤ 0.05 was considered significant.
Results
Patient characteristics
All 108 patients enrolled in our study were pathologic-
ally diagnosed with HCC and/or colorectal cancer. The
age for all patients was 60.57 ± 10.80 (mean ± SD) years
(range: 31–80). Among the 108 participants, patients are
divided into two cohorts. As summarized in Table 1, no
significant difference was observed in the distribution of
age (P = 0.887), gender (P = 0.473), Child-Pugh score (P =
0.553) and extra-hepatic metastasis (P = 0.838) between
the two cohorts. The male: female ratio is 1:1.11 and
1:0.78 in two cohorts. In all 108 patients, in the neo-
adjuvant treatments before operation, five cases received
chemotherapy, one case received portal vein embolization
(PVE) and two cases received transcatheter arterial
chemoembolization (TACE); in adjuvant treatments after
operation, 18 cases received chemotherapy, 16 cases
received lipiodol-iodine-131, two cases received TACE
only or combined with chemotherapy.
Expression of wtERa, ERa36 and ER-beta in 76 primary
HCC tissues
We performed an IHC analysis of wtERa, ERa36 and ER-
beta expression in two HCC cohorts. Representative IHC
results of cohort P (primary HCC) are shown in Fig. 1.
Similar to the findings of breast cancer [13], wtERa
expression was primarily in the cell membrane and cyto-
plasm of liver cells and significantly lower in HCC tissues
than in adjacent non-tumor tissues (mean score 2.345 vs.
2.620, P < 0.010, Fig. 3). In contrast, ERa36 expression was
primarily in cytoplasm of liver cells and significantly
higher in HCC tissues than in adjacent non-tumor tissues
(mean score 3.184 vs. 2.888, P < 0.008, Fig. 3). ERb expres-
sion was primarily in cytoplasm of liver cells and lower in
HCC tissues than in adjacent non-tumor tissues (mean
score 1.566 vs. 1.770, P = 0.139, Fig. 3).
Expression of wtERa, ERa36 and ER-beta in 32 mCRC HCC
tissues
Representative IHC results of cohort S (metastatic HCC)
are shown in Fig. 2. It was found that the expression of
either wtERa or ERb between mCRC HCC tissues and
adjacent non-tumor tissues was not significantly different
(P = 0.944 and P = 0.487) (Fig. 3). Interestingly, ERa36 ex-
pression was significantly lower in mCRC HCC tissues
than in adjacent non-tumor tissues (mean score 1.883 vs.
3.234, P < 0.001) (Fig. 3). The expression of wtERa of both
tumor and non-tumor tissues in cohort P was lower than
in cohort S (P < 0.001). The expression of ERa36 in the
tumor tissues of the cohort P was higher than in the cohort
S (P < 0.001). There was no significant difference in ERb
expression between the cohort P and the cohort S (Fig. 3).
Correlation analysis of the expression of wtERa, ERa36
and ER-beta with clinical features
We further correlated the expression of wtERa, ERa36
and ERb with clinical features and patient survival. Using
median expression values as cutoff points, the levels of
wtERa, ERa36 and ERb were evaluated as ordinal variables
(high expression vs. low expression).
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In cohort P, wtERa was positively correlated with gen-
der and age, but it was negatively correlated Inter-
national Normalized Ratio (INR), size of the largest
tumor, tumor recurrence or metastasis, and adjuvant
treatments after operation (Table 2). ERa36 was posi-
tively correlated with the status of adjacent non-tumor
liver tissues and liver cirrhosis, but it was negatively
correlated with extra-hepatic metastasis and pathological
grade. ERb was also positively correlated with gender
and age, but it was negatively correlated with Inter-
national Normalized Ratio (INR) and HBsAg status
(Table 2). WtERa was negatively associated with OS and
DFS in cohort P, while ERa36 and ERb were not associ-
ated with OS or DFS (Fig. 4). In cohort S, we did not
find statistically significant changes in the expression of
wtERa, or ERa36 or ERb under different clinical features,
such as gender, age, vascular invasion, non-tumor liver
status, HBsAg status, and survival.
The univariate analysis of the hazard ratios of clinical
features and biomarkers for OS were summarized in
Table 3 (cohort P). The result of the univariate analysis
showed that among the clinical characteristics, gender,
tumor number, tumor size, vascular invasion, extra-hepatic
metastasis, neo-adjuvant treatments, adjuvant treatments,
and liver cirrhosis were associated with patients’ OS, but
wtERa, ERa36 and ERb were not (Table 3). In multivariate
analysis, only gender, tumor size, adjuvant treatments, and
liver cirrhosis appeared to be independent prognostic fac-
tors for OS and DFS prediction (P < 0.01, Table 3). Vascular
invasion was also an independent prognostic factor for
Fig. 1 Representative photomicrographs of the immunohistochemical analysis of wtERa, ERa36 and ER-beta protein expression in 76
primary HCC (cohort P)
Fig. 2 Representative photomicrographs of the immunohistochemical analysis of wtERa, ERa36 and ER-beta protein expression in 32 mCRC HCC
tissues (cohort S)
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DFS (P = 0.037). WtERa, ERa36 and ERb levels were not
significant markers for OS and DFS in the multivariate
analysis (data not shown).
TCGA data analysis of ERa transcripts and wtERa, ERb
mRNA expression
Because ERa36 has a different 3’ untranslated region
end [11] from wtERa, wtERa and ERa36 can be dis-
criminated by two alternate terminator (AT) events.
In TCGA LIHC data set, a total of 121 HCC tumor
tissues and/or 50 adjacent non-tumor tissues were in-
cluded in our research for alternative splicing analysis
of ERa and mRNA expression. In general, the Percent
Spliced In (PSI) value of ERa36 was significant higher
in HCC tissues than in adjacent non-tumor tissues
(mean value 0.019 versus 0.004, P < 0.001, Fig. 5). In
contrast, the PSI value of ERa66 was also significant
higher in adjacent non-tumor tissues than in HCC
tissues (mean value 0.996 versus 0.981, P < 0.001).
Using Kendall tau rank correlation, we found that the
PSI value of ERa36 was correlated with tumor status
(P = 0.003), tumor grade (P = 0.002), and new tumor
events (P =0.001). These findings support that ERa36
functions against ERa66, with the former being onco-
genic but the latter being protective [13, 14], suggest
that ERa36 may contribute to the development and/or
progression of HCC. The high PSI value of ERa36
was not significantly correlated with risk factors,
Fig. 3 Mean expression scores of wtERa, ERa36 and ER-beta in primary HCC compared to secondary HCC. (a) Decreased wtERa (P < 0.010) and
increased ERa36 (P < 0.008) in tumor tissues in Cohort P; and (b) Decreased ERa36 (P < 0.001) in tumor tissues in Cohort S. P-values were
calculated using the paired sample t test. wtERa, blue; ERa36, green; ERb, brown; T, tumor tissue; N, adjacent non-tumor tissue; error bars,
95 % confident interval
Table 2 Correlation analysis of the expression of wtERa, ERa36
and ER-beta with clinical features (cohort P)





wtERa Gender (Female vs. Male) 0.662 0.000
Age (>58 vs. ≤58) 0.276 0.007
International Normalized Ratio −0.442 0.000
Size of the largest tumor
(>5 cm vs. ≤5 cm)
−0.306 0.003
Intra-hepatic recurrence (Yes vs. No) −0.308 0.003
Extra-hepatic metastasis (Yes vs. No) −0.310 0.002
Adjuvant treatments after operation
(Yes vs. No)
−0.348 0.001
ERa36 Non-tumour liver (Cirrhosis vs.
Fibrosis vs. Normal)
0.270 0.009
Extra-hepatic metastasis (Yes vs. No) −0.274 0.007
Pathological Grade (Poor vs.
Moderate vs. Well)
−0.274 0.007
Liver cirrhosis (Yes vs. No) 0.267 0.009
ERb Gender (Female vs. Male) 0.234 0.023
Age (>58 vs. ≤58) 0.308 0.002
International Normalized Ratio −0.273 0.009
HBsAg (+ vs. -) −0.377 0.000
a Correlation is significant at the 0.01 level (2-tailed)
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AJCC TNM & pathological stage, vascular invasion,
Child-pugh classification, and age at diagnosis. More-
over, when we divided the 121 HCC patients into two
groups using median PSI value as a cutoff point, we
did not find significant changes in survival between
two groups (log-rank P > 0.05).
To further reveal the relationships between PSI value of
ERa36 mRNA and the levels of ERa and ERb mRNA, we
found that ERa36 was significantly negatively correlated
with ERa (Pearson correlation efficient = −0.403, P < 0.001).
No significantly correlation was found between ERa36 and
ERb or between wtERa and ERb. The expression of wtERa
Fig. 4 Kaplan-Meier survival curves for wtERa in cohort P. Using the median value as cutoff, cohort P was divided into two groups: each group with 38
cases. a Disease-free survival, b Overall survival (Blue dotted line, low expression; Green dotted line, high expression; Vertical axis, survival function)
Table 3 Univariate and multivariate analyses of clinical features and biomarkers with patients’ overall survival (cohort P)
Univariate analysis Multivariate analysis
HR(95 % CI) P value a HR(95 % CI) P valuea
wtERa high vs. low 0.455 (0.202–1.025) 0.058 0.519 (0.156–1.723) 0.284
ERa36 high vs. low 1.070 (0.501–2.282) 0.862 2.853 (0.843–9.654) 0.092
ERb high vs. low 1.121 (0.524–2.402) 0.768 1.151 (0.342–3.867) 0.820
Age >58 vs. ≤58 1.536 (0.698–3.380) 0.286 1.767 (0.503–6.205) 0.375
Gender Female vs. Male 0.314 (0.125–0.787) 0.013 0.186 (0.047–0.733) 0.016
AFP (ng/ml) >18 vs. ≤18 0.896 (0.415–1.935) 0.780 0.978 (0.327–2.925) 0.969
Tumor number Multiple vs. Single 4.660 (2.069–10.495) 0.000 2.065 (0.635–6.719) 0.228
Tumor size (cm) >5 vs. ≤5 3.528 (1.635–7.612) 0.001 4.679 (1.441–15.195) 0.010
Vascular invasion Yes vs. No 2.695 (1.165–6.231) 0.020 0.282 (0.058–1.361) 0.115
Intra-hepatic recurrence Yes vs. No 2.118 (0.967–4.640) 0.061 0.718 (0.192–2.689) 0.623
Extra-hepatic metastasis Yes vs. No 2.741 (1.216–6.181) 0.015 2.177 (0.714–6.638) 0.171
Neo-adjuvant treatments Yes vs. No 3.851 (1.121–13.230) 0.032 2.132 (0.341–13.318) 0.418
Adjuvant treatments Yes vs. No 4.522 (1.393–14.687) 0.012 11.204 (2.231–56.266) 0.003
Liver cirrhosis Yes vs. No 3.377 (1.258–9.062) 0.016 5.202 (1.324–20.435) 0.018
HBsAg + vs. - 0.542 (0.241–1.215) 0.137 0.596 (0.153–2.317) 0.455
Abbreviation: HR hazard ratio, OS overall survival, CI confidence interval
Significant data are highlighted in bold. a Correlation is significant at the 0.01 a level (2-tailed)
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mRNA was higher in adjacent non-tumor tissues
than in HCC tissues (mean value 221.54 versus
1254.00, P < 0.001, Fig. 5).
Discussion
Previous reports suggest that the levels of wtERa and
ERb expression were downregulated in HCC than in
chronic liver disease and ER-α36 was upregulated in
HCC [15, 16]. However, the relationship between differ-
ent ERs and clinical features in primary or secondary
HCC has not been established. In this study, we analyzed
the expression patterns of wtERa, ERa36 and ERb, and
studied the predictive and prognostic value of ERs in
HCC using two independent cohorts and one publicly
available TCGA data set. Findings from our study indi-
cated that the mRNA expression of wtERa was nega-
tively correlated with ERa36 transcript in patients with
HCC (the TCGA data set). This finding was confirmed
at protein levels analyzed by IHC of primary HCC pa-
tients from our hospital. Importantly, we have demon-
strated that compared with non-tumor tissues, the
expression of ERa36 is increased in primary HCC but
decreased in secondary HCC, showing opposite expres-
sion patterns of ERa36 between primary HCC and sec-
ondary HCC. Furthermore, the expression of ERa36 in
the primary HCC is much higher than in the secondary
HCC. Therefore, the expression of ERa36 may be used
to differentiate the primary HCC and the secondary one.
The estrogen pathway plays a critical role in tumori-
genesis, metastasis, and response to certain therapies of
HCC [4, 16, 17]. The role of wtER in HCC was investi-
gated early in 1980s [18]. Due to multiple variants of
ERa and ERb, the actual role of wtER in HCC was too
complex to be defined. Several studies have reported
that the expression of wtER was less in tumor tissues
than in adjacent normal tissues [19, 20], which was in
line with our findings on wtERa. These results indicate
that wtERa may exhibit a protective role in HCC [21].
The downregulation of wtERa in HCC tumor tissues can
be due to the hypermethylation of CpG sites in the pro-
moter region of wtERa [22]. The expression of ERs can
also be regulated by miRNA or lncRNA [23]. For ex-
ample, the expression of wtERa in tumor tissues may also
be inhibited by mir-18a, which is further controlled by
tumor suppress gene P53 [24, 25]. Villa et al. reported that
wtER and an exon 5-deleted ER variant could be used as
classification predictors for survival of HCC [26]. The up-
regulation of wtERa led to the prolonged overall survival
and disease free survival in primary HCC in our study.
Interestingly, the expression of novel ERa36 is higher in
tumor tissues than in adjacent non-tumor tissues in our
study. This finding is in line with one early report showing
that that the levels of ERa36 mRNA were gradually
increased from normal liver to cirrhotic liver and to HCC
liver [15]. It thus appears that HCC tumor tissues are
associated with the increased level of ERa36 but the de-
creased level of wtERa. The opposite expression of wtERa
Fig. 5 Mean Percent Spliced In (PSI) values of ERa36 and mRNA of wild type ERa in tumor (T) HCC tissues and adjacent normal (N) liver tissues. a.
mean PSI value of ERa36 showed that the percentage of ERa36 transcript was higher in tumor tissues than in non-tumor tissues (P < 0.001, Error
bars, 95 % CI); b. The mRNA expression level of wtERa was lower in tumor tissues than in non-tumor tissues (P < 0.001, Error bars, 95 % CI)
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and ERa36 in HCC may suggest differential roles of ERs
in HCC. It has been reported that wtERa functions as a
tumor suppressor gene in some cancers including HCC
[21]. Though the function of ERa36 in HCC has not yet
been defined, it is known to promote the growth of other
cancers such as breast cancer cells [27]. The fact that
wtERa is reduced in HCC and wtERa functions as a tumor
suppressor may well explained the failure of early trial of
tamoxifen, as wtER antagonist, to treat HCC [6, 28]. How-
ever, recent studies have indicated that tamoxifen may
inhibit HCC via ER-independent mechanisms [29].
In this study, we fail to show the association of ERa36
upregulation with survival in either primary HCC or sec-
ondary HCC from CRC. The finding is unexpected and
the negative result may be due to the size of samples.
The prognostic value of ERa36 has been demonstrated
in some other cancers such as breast cancer [13, 28]. As
a new oncogenic molecule. ERa36 may facilitate the
growth, invasion and metastasis of cancers via various
pathways including cancer stem/progenitor cells, and
AKT survival signaling [28]. It is thus reasonable to con-
sider it as a potential therapeutic target [29]. The finding
of the increased ERa36 in HCC may suggest that HCC
patients may also benefit from targeting ERa36.
Conclusions
Using independent patient cohorts from primary/secondary
HCC and TCGA database, we have determined the
expression patterns of wtERa, ERa36 and ERb and their
association with clinical characteristics. We have shown
that the expressions of wtER and ERa36 were in opposite
directions in primary HCC, and that ERa36 was increased
in primary HCC tissues while decreased in secondary HCC.
The high levels of wtERa mRNA appears to predict better
survival of patients with HCC. The mechanism responsible
for the abnormal expression of ERs in HCC remains un-
known. Our current findings suggest that the expression of
ERa36 protein could be a useful tool to discriminate pri-
mary HCC from secondary HCC patients from CRC, and
that its oncogenic role may render it as a therapeutic target.
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